A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686].
暂无分享,去创建一个
K. Gelmon | L. Seymour | M. Tsao | D. Tu | P. Bedard | S. Chia | E. Amir | M. Cabanero | J. Hilton | D. Villa | R. Goodwin | H. Ritter